In vitro activity of Schinus terebinthifolius extract and fractions against Sporothrix brasiliensis.
Journal
Memorias do Instituto Oswaldo Cruz
ISSN: 1678-8060
Titre abrégé: Mem Inst Oswaldo Cruz
Pays: Brazil
ID NLM: 7502619
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
03
2022
accepted:
05
09
2022
entrez:
5
10
2022
pubmed:
6
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
Sporothrix brasiliensis is the causative agent of zoonotic cases of sporotrichosis in Brazil and is associated with atypical and severe presentations in cats, dogs, and humans. Sporotrichosis treatment is usually time- and cost-consuming, sometimes with poor response and host toxicity. Schinus terebinthifolius has proven efficacy against bacteria and fungi of clinical interest. To determine the in vitro activity of S. terebinthifolius against S. brasiliensis. Five S. brasiliensis isolates and three reference strains were subjected to a hydroethanol extract derived from the leaves of S. terebinthifolius and its fractions. The minimal inhibitory concentration (MIC) was determined using the broth microdilution method according to the M38-A2 CLSI guidelines. Also, the fungicidal/fungistatic activity of the extract and fractions was studied. The crude extract of S. terebinthifolius inhibited the growth of S. brasiliensis (MIC: 0.5-1.0 µg/mL), while the partitioned extracts dichloromethane, ethyl acetate, and butanol demonstrated growth inhibition at 8 µg/mL due to a fungistatic activity. Due to its in vitro efficacy against S. brasiliensis and its known pharmacological safety, S. terebinthifolius is a candidate to be tested using in vivo models of sporotrichosis.
Sections du résumé
BACKGROUND
BACKGROUND
Sporothrix brasiliensis is the causative agent of zoonotic cases of sporotrichosis in Brazil and is associated with atypical and severe presentations in cats, dogs, and humans. Sporotrichosis treatment is usually time- and cost-consuming, sometimes with poor response and host toxicity. Schinus terebinthifolius has proven efficacy against bacteria and fungi of clinical interest.
OBJECTIVE
OBJECTIVE
To determine the in vitro activity of S. terebinthifolius against S. brasiliensis.
METHODS
METHODS
Five S. brasiliensis isolates and three reference strains were subjected to a hydroethanol extract derived from the leaves of S. terebinthifolius and its fractions. The minimal inhibitory concentration (MIC) was determined using the broth microdilution method according to the M38-A2 CLSI guidelines. Also, the fungicidal/fungistatic activity of the extract and fractions was studied.
FINDINGS
RESULTS
The crude extract of S. terebinthifolius inhibited the growth of S. brasiliensis (MIC: 0.5-1.0 µg/mL), while the partitioned extracts dichloromethane, ethyl acetate, and butanol demonstrated growth inhibition at 8 µg/mL due to a fungistatic activity.
MAIN CONCLUSIONS
CONCLUSIONS
Due to its in vitro efficacy against S. brasiliensis and its known pharmacological safety, S. terebinthifolius is a candidate to be tested using in vivo models of sporotrichosis.
Identifiants
pubmed: 36197404
pii: S0074-02762022000101125
doi: 10.1590/0074-02760220063
pmc: PMC9524759
pii:
doi:
Substances chimiques
Antifungal Agents
0
Butanols
0
Complex Mixtures
0
Methylene Chloride
588X2YUY0A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e220063Références
J Ethnopharmacol. 2012 Sep 28;143(2):631-8
pubmed: 22867638
PLoS One. 2020 Oct 14;15(10):e0240658
pubmed: 33052959
J Ethnopharmacol. 2015 Dec 4;175:490-8
pubmed: 26453933
PLoS One. 2016 Mar 31;11(3):e0152796
pubmed: 27031728
J Appl Microbiol. 2013 Mar;114(3):672-9
pubmed: 23190078
An Bras Dermatol. 2017 Sep-Oct;92(5):606-620
pubmed: 29166494
PLoS Negl Trop Dis. 2015 Dec 01;9(12):e0004190
pubmed: 26623643
Braz J Microbiol. 2021 Mar;52(1):73-80
pubmed: 32476087
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28739796
J Ethnopharmacol. 2005 Jan 15;96(3):563-8
pubmed: 15619579
PLoS One. 2020 May 13;15(5):e0229630
pubmed: 32401759
Acta Odontol Latinoam. 2012;25(3):287-92
pubmed: 23798075
Mem Inst Oswaldo Cruz. 2017 May;112(5):376-381
pubmed: 28443986
J Ethnopharmacol. 2009 Dec 10;126(3):468-73
pubmed: 19781616
PLoS Pathog. 2017 Jan 19;13(1):e1006077
pubmed: 28103311
Trends Microbiol. 2007 Jun;15(6):279-89
pubmed: 17433686
Rev Iberoam Micol. 2019 Jul - Sep;36(3):139-141
pubmed: 31171430
Mycopathologia. 2020 Oct;185(5):813-842
pubmed: 32052359
Int Immunopharmacol. 2008 Nov;8(11):1552-60
pubmed: 18672096
Open Microbiol J. 2011;5:96-106
pubmed: 21915230
PLoS Negl Trop Dis. 2018 Apr 23;12(4):e0006434
pubmed: 29684015
Med Mycol. 2020 Jan 1;58(1):141-143
pubmed: 31220310
PLoS Negl Trop Dis. 2018 Mar 9;12(3):e0006169
pubmed: 29522522
Antimicrob Agents Chemother. 2021 Feb 16;:
pubmed: 33593845
mSphere. 2017 Apr 12;2(2):
pubmed: 28435886
Mycoses. 2015 Nov;58(11):652-8
pubmed: 26404561
PLoS Negl Trop Dis. 2021 Aug 30;15(8):e0009693
pubmed: 34460830
PLoS Negl Trop Dis. 2019 Feb 28;13(2):e0007219
pubmed: 30817761